Chardan Capital Reiterates Buy Recommendation for Ocular Therapeutix with 96.51% Upside Potential

Chardan Capital has maintained a "Buy" recommendation for Ocular Therapeutix (OCUL) with an analyst price forecast suggesting a 96.51% upside from its latest reported closing price of $10.90/share. The average one-year price target for OCUL is $21.42/share, and the projected annual revenue is 142MM, an increase of 154.13%. The projected annual non-GAAP EPS is -0.63.